Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years.

Trial Profile

Immunogenicity and Safety of Multiple Formulations of an A/H1N1 Pandemic Vaccine in Healthy Subjects Aged 6 Months to 9 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi; sanofi pasteur
  • Most Recent Events

    • 08 Jul 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 07 Jan 2011 Results published in Vaccine.
    • 16 Dec 2009 Immunogenicity results after single vaccination published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top